Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

(2018) Neal I. Lindeman et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

(2018) David R. Spigel et al.   Journal of Thoracic Oncology

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

(2018) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

(2017) Dong-Wan Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

(2017) Byoung Chul Cho et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

(2017) Alice T Shaw et al.   LANCET ONCOLOGY

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers

(2017) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

(2017) Michaël Duruisseaux et al.   Oncotarget

The role of the ALK receptor in cancer biology

(2016) B. Hallberg et al.   ANNALS OF ONCOLOGY

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014

(2016) Benjamin J. Solomon et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

(2016) Tatsuya Yoshida et al.   JOURNAL OF CLINICAL ONCOLOGY

A Case of ALK- Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

(2016) Yoon Jin Cha et al.   Journal of Thoracic Oncology

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib

(2016) Shiro Fujita et al.   Journal of Thoracic Oncology

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants

(2016) Yoon Jin Cha et al.   Journal of Translational Medicine

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

(2016) Dong-Wan Kim et al.   LANCET ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Characteristics, treatment patterns, and survival among ALK + non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study

(2016) Jacques Cadranel et al.   LUNG CANCER

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors

(2016) Delphine Levacq et al.   LUNG CANCER

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

(2015) Helen Y. Zou et al.   CANCER CELL

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

(2015) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

(2015) Daniel B. Costa et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

(2015) Lynette M. Sholl et al.   Journal of Thoracic Oncology

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

(2015) Gorjan Hrustanovic et al.   NATURE MEDICINE

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

(2015) E. M. Tricker et al.   Cancer Discovery

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

(2015) Helena A. Yu et al.   JAMA Oncology

Molecular mechanisms of epithelial–mesenchymal transition

(2014) Samy Lamouille et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

(2012) Ramaswamy Govindan et al.   CELL

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

(2012) Andrew J. Weickhardt et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

The biology and treatment of EML4-ALK non-small cell lung cancer

(2010) Takaaki Sasaki et al.   EUROPEAN JOURNAL OF CANCER

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer

(2008) Y. L. Choi et al.   CANCER RESEARCH

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH